MassARRAY-based simultaneous detection of hotspot somatic mutations and recurrent fusion genes in papillary thyroid carcinoma: the PTC-MA assay.
Chiara Pesenti, Marina Muzza, Carla Colombo...
https://pubmed.ncbi.nlm.nih.gov/29214440Actively Recruiting
All Genders
ID05766098
Definition of Mutational Profile of Papillary Thyroid Tumors by Mass ARRAY Technology
Led by Istituto Auxologico Italiano · Updated on 2024-10-08
600
Participants Needed
1
Research Sites
8 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying papillary thyroid cancer (PTC) to understand the genetic mutations present in these tumors, especially in the MAP kinase pathway. The study aims to analyze the mutational profile of many PTC tumors to help predict patient prognosis and how targeted treatments might work. This research uses a specialized technology called Mass ARRAY to identify common genetic changes in PTCs in a quick and cost-effective way. The study involves analyzing tumor samples from patients with papillary thyroid cancer using the PTC-MA platform. This platform detects multiple key mutations and rearrangements in the cancer cells through genetic testing called genotyping. The study is observational, focusing on collecting and characterizing genetic information without administering treatments. Participants provide tumor tissue samples that researchers examine for genetic mutations. The team will correlate these molecular profiles with the patients’ clinical features and outcomes over a period of up to eight years. The main outcome measured is the mutational profile of the PTC tumors. There is no intervention beyond genetic testing, and participants are monitored through their usual clinical care.
CONDITIONS
Brief Title
Definition of Mutational Profile of Papillary Thyroid Tumors by Mass-ARRAY
Who Can Participate
All Genders
Eligibility Criteria
You may qualify if you...
- Patients with papillary thyroid cancer
- Patients whose tumor tissue can be recovered for genetic analysis
You will not qualify if you...
- Patients who did not give consent
- Patients lost to follow-up
- Tumor samples not suitable for genetic analysis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Sample Collection
Duration - Up to 8 years
Tumor tissue samples are collected for genetic analysis to characterize the mutational profile.
Visits as needed for tissue recovery and analysis
Long-term Monitoring
Duration - Up to 8 years
Participants are observed over time to monitor mutational profiles and clinical outcomes.
Follow-up visits depending on clinical care
Trial Site Locations
Total: 1 location
1
Istituto Auxologico Italiano
Milan, MI, Italy, 20145
Actively Recruiting
Loading map...
Research Team
M
Marina Muzza, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here